Vivo Bio Tech Limited - Format for Disclosure of Related Party Transactions for H1/2022-2023 i.e. from 01st April 2022 to 30th September 2022

S.No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction (1. Sale of goods or services 2. Purchase of goods or services 3. Loan 4. Inter Corporate Deposit 5. Advance 6. Investment 7. Any other transcation 8. Purchase of fixed assets 9. Sale of fixed assets 10. Interest paid 11. Interest received 12. Remuneration 13. Dividend paid 14. Dividend received)	Value of the related party transaction as approved by the audit committee	Remakrs of approval by Audit Committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.								
										In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary					Opening balance (As on Apr 01, 2022)	Closing balance (As on Sep 30, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Vivo Bio Tech Limited	VivoBio Consulting Services Private Limited	Subsidiary	Investment in Equity	-		-	100,000	100,000									
2	Vivo Bio Tech Limited	Surlogic Life Consultancy Private Limited	Subsidiary	Investment in Equity	-		-	100,000	100,000									
3	Vivo Bio Tech Limited	Vivo Bio Discovery Services Private Limited	Subsidiary	Investment in Equity	-		-	100,000	100,000									
4	Vivo Bio Tech Limited	Vivo Bio Labs Private Limited	Subsidiary	Investment in Equity	-		-	100,000	100,000									
5	Vivo Bio Tech Limited	VivoBio Consulting Services Private Limited	Subsidiary	Loans & Advances	-		-	10,125,120	10,125,120									
6	Vivo Bio Tech Limited	Surlogic Life Consultancy Private Limited	Subsidiary	Loans & Advances	-		-	3,412,250	3,412,250									
7	Vivo Bio Tech Limited	Vivo Bio Discovery Services Private Limited	Subsidiary	Loans & Advances	-		-	606,000	606,000									
8	Vivo Bio Tech Limited	Vivo Bio Labs Private Limited	Subsidiary	Loans & Advances	-		-	1,877,900	1,877,900									
9	Vivo Bio Tech Limited	M Kalyan Ram	Wholetime Director	Remuneration	430,602		430,602	-										
10	Vivo Bio Tech Limited	K Sri Kalyan	Wholetime Director & CFO	Remuneration	445,002		445,002	-										
11	Vivo Bio Tech Limited	Jyotika Aasat	Company Secretary	Remuneration	381,989		381,989	-										
12	Vivo Bio Tech Limited	Sankaranarayanan Alangudi	Wholetime Director	Remuneration	900,000		900,000											
13	Vivo Bio Tech Limited	Viswanath Kompella	Advisor and Common Promoter	Remuneration	7,500,000		7,500,000	-										
14	Vivo Bio Tech Limited	Madhavi Latha	Advisor and Common Promoter	Remuneration	9,000,000		9,000,000	-										
15	Vivo Bio Tech Limited	Virinchi Health Care Private Limited	Common Promoter	Guarantee/Collateral Given	79,600,000		72,100,000	695,000,000	767,100,000									
	Total				**98,451,593**		**90,951,593**	**711,421,270**	**783,521,270**									